Table 3.
Pharmacodynamic parameters of phase II antioxidant gene expression estimated from the designated PK-PD model shown in Figure 1.
| mRNA | Emax (CV%) | EC50(μg/mL) (CV%) | τ (h) (CV%) | kin (h-1) (CV%) |
|---|---|---|---|---|
| Ho1 | 13.2 (42.9) | 0.368 (45.7) | 0.767 (fixed) | 1.306 (57.7) |
| Nqo1 | 7.330 (35.6) | 1.738 (42.3) | 0.710 (fixed) | 1.436 (79.3) |
| Ugt1a1 | 8.520 (63.2) | 1.360 (62.2) | 0.751 (fixed) | 1.771 (70.2) |